摘要
目的 分析新辅助放疗（ NRT）及新辅助放化疗（NCRT）及单纯手术（S）对中晚期中低位直肠癌的临床价值.方法 选取139例中低位直肠癌患者,分成3组,NRT组给予术前放疗（50 Gy/25次,共5周）,NCRT组予以术前放化疗（卡培他滨联合奥沙利铂＋放疗）方案,S组直接手术.随访分析3组患者保肛率及3年生存率.结果 NRT及NCRT组保肛率分别为74.47％（35/47）和73.91％（34/46）,较S组的54.35％（25/46）明显提高（x2=4.111、3.827,P=0.043、0.050）,3组1、2、3年生存率差异无统计学意义（均P＞ 0.05）,NRT及NCRT第1年生存率分别为87.23％（41/47）和88.89％（40/45）,与S组97.83％（45/46）比较,差异无统计学意义（x2=4.611,P=0.100）.结论 NRT及NCRT在提高保肛率方面有一定优势,但3年生存率无明显提高。
Objective To study the clinical value of neoadjuvant radiotherapy （NRT）,neoadjuvant chemoradiotherapy （NCRT） or surgery alone （S） in treatment of middle and low rectal cancer.Methods 139 cases were divided into 3 groups：47 cases were given NRT （50 Gy/25 f/5 w） as group NRT,46 cases were given NCRT （Capox＋ radiotherapy） as group NCRT,and the remaining 46 cases were treated with surgery alone as group S.Patients in 3 groups were followed-up for 3 years for the observation of the rates of anuspreserving and 3-year survival rates.Results Compared with the patients in group S,the rates of anuspreserving in group NRT and NCRT were significant improvement [74.47 % （35/47） and 73.91% （34/46） vs 54.35 % （25/46）],（x2 =4.111,3.827; P=0.043,0.050）.The 1,2,3-year survival rates of the 3 groups had no significantly different （P 〉0.05）.However,the 1-year survival rates might be lower in group NRT and group NCRT than that in group S [87.23 % （41/47） and 88.89 % （40/45） vs 97.83 % （45/46）] （x2 =4.611,P =0.100）.Conclusion NRT and NCRT can improve the rate of anus-preserving,but might not improve the 1,2,3-year survival rate,instead,the death rate may increase in the first year
出处
《肿瘤研究与临床》
CAS
2011年第10期681-683,共3页
Cancer Research and Clinic
关键词
放射疗法
辅助
化学疗法
辅助
中低位直肠肿瘤
保肛率
生存率
Radiotherapy, adjuvant
Chemotherapy, adjuvant
Middle and low rectal neoplasms
Rate of anus-preserving
Survival rate
